VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

S. aureus ClfA Protein Vaccine
Vaccine Information
  • Vaccine Name: S. aureus ClfA Protein Vaccine
  • Target Pathogen: Staphylococcus aureus
  • Target Disease: Staph infections
  • Vaccine Ontology ID: VO_0004047
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: Recombinant ClfA protein (Josefsson et al., 2001).
  • ClfA gene engineering:
    • Type: Recombinant protein preparation
    • Description: Expression and purification of recombinant proteins.Vector pCF40 expressed rClfA truncate rClfA40‐559 (Josefsson et al., 2001).
    • Detailed Gene Information: Click Here.
  • Adjuvant: complete Freunds adjuvant
  • Immunization Route: subcutaneous injection
Host Response

Mouse Response

  • Host Strain: NMRI
  • Vaccination Protocol: Purified rClfA region A, comprising residues 40–559 (rClfA40‐559), and BSA (Sigma Chemical) were dissolved in physiologic saline and were emulsified 1:1 in Freund's complete adjuvant (Difco Laboratories). In total, 200 μL of the emulsion containing 30 μg of protein was injected subcutaneously (sc) on day −21 ( /group). Booster immunization with 30 μg of protein in physiologic saline:Freund's incomplete adjuvant 1:1 sc was done on day −10 (Josefsson et al., 2001).
  • Challenge Protocol: On day 0, the mice were challenged iv with 1.6 x 107 cfu/mouse of wild‐type S. aureus strain Newman (Josefsson et al., 2001).
  • Efficacy: Mice immunized with rClfA40‐559 had less severe arthritis than did the control BSA‐immunized group throughout the experiment. Both the severity of synovitis and the extent of joint destruction were markedly less pronounced in mice immunized with rClfA40‐559 than in the BSA control group (Josefsson et al., 2001).
References
Josefsson et al., 2001: Josefsson E, Hartford O, O'Brien L, Patti JM, Foster T. Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. The Journal of infectious diseases. 2001; 184(12); 1572-1580. [PubMed: 11740733].